Literature DB >> 15202817

Pulse high volume hemofiltration.

A Brendolan1, V D'Intini, Z Ricci, M Bonello, R Ratanarat, G Salvatori, V Bordoni, M De Cal, E Andrikos, C Ronco, G Salvadori.   

Abstract

The sepsis syndrome is the most common cause of acute renal failure and multiple organ dysfunction in critically ill subjects and continues to have an alarmingly high mortality. Normal immune homeostasis is interrupted by a complex storm of inflammatory mediators responsible for the deleterious effects. Extracorporeal blood purification techniques can confer benefits in sepsis by proven non-specific removal of these mediators (pro- or anti-inflammatory), and provide a logical and adequate approach to treat this syndrome. High volume hemofiltration (HVHF) has had the most dramatic effect conferring benefits in hemodynamics, reduction in vasopressor doses and improvement in survival. "Pulse HVHF" is the latest approach which may offer the most efficient results: a daily schedule of 6-8 hours followed by standard CVVH. This paper describes the rationale and potential of this technique. Reliability and tolerance of this technique and biological effects are described.

Entities:  

Mesh:

Year:  2004        PMID: 15202817     DOI: 10.1177/039139880402700508

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  10 in total

Review 1.  Study on acute recent stage pancreatitis.

Authors:  Ye-Chen Feng; Min Wang; Feng Zhu; Ren-Yi Qin
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

2.  Refractory status epilepticus, serious rhabdomyolysis, acute liver injury, and pancytopenia after a massive intake of ethyl methanesulfonate: a case report.

Authors:  Hiroyuki Yamazaki; Shogo Tajima; Takahiro Takeuchi
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 3.  Clinical review: blood purification for sepsis.

Authors:  Thomas Rimmelé; John A Kellum
Journal:  Crit Care       Date:  2011-02-16       Impact factor: 9.097

4.  Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival.

Authors:  Ranistha Ratanarat; Alessandra Brendolan; Pasquale Piccinni; Maurizio Dan; Gabriella Salvatori; Zaccaria Ricci; Claudio Ronco
Journal:  Crit Care       Date:  2005-04-28       Impact factor: 9.097

5.  Study protocol: the DOse REsponse Multicentre International collaborative initiative (DO-RE-MI).

Authors:  Detlef Kindgen-Milles; Didier Journois; Roberto Fumagalli; Sergio Vesconi; Javier Maynar; Anibal Marinho; Irene Bolgan; Alessandra Brendolan; Marco Formica; Sergio Livigni; Mariella Maio; Mariano Marchesi; Filippo Mariano; Gianpaola Monti; Elena Moretti; Daniela Silengo; Claudio Ronco
Journal:  Crit Care       Date:  2005-06-14       Impact factor: 9.097

6.  Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance.

Authors:  Claudio Ronco
Journal:  Crit Care       Date:  2005-02-08       Impact factor: 9.097

7.  Effect of pulse high-volume hemofiltration on Toll-like receptor in patients with severe sepsis.

Authors:  Ning Zhang; Jian Zhang; Zhuo Cao; Liancheng Deng; Yifen Wu; Hong Liu; Zeliang Qiu
Journal:  Exp Ther Med       Date:  2016-06-23       Impact factor: 2.447

Review 8.  Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications.

Authors:  Gianluca Villa; Mauro Neri; Rinaldo Bellomo; Jorge Cerda; A Raffaele De Gaudio; Silvia De Rosa; Francesco Garzotto; Patrick M Honore; John Kellum; Anna Lorenzin; Didier Payen; Zaccaria Ricci; Sara Samoni; Jean-Louis Vincent; Julia Wendon; Marta Zaccaria; Claudio Ronco
Journal:  Crit Care       Date:  2016-10-10       Impact factor: 9.097

Review 9.  Recent evolution of renal replacement therapy in the critically ill patient.

Authors:  Claudio Ronco
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

10.  Renal Replacement Therapy in Acute Kidney Failure due to Rhabdomyolysis.

Authors:  G Maggi; F Quinteros Hinojosa; M J Villagran; E Guasch Arévalo; F Gilsanz Rodríguez
Journal:  Case Rep Crit Care       Date:  2012-04-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.